Raleigh Capital Management’s Quest Diagnostics DGX Stock Holding History

Raleigh Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.7K	Sell	8 -17	-68%	-$3.34K	﹤0.01%	443
2026 Q1	$4.9K	Buy	+25	New	+$4.86K	﹤0.01%	428
2025 Q1	–	Sell	-5	Closed	-$754	–	684
2024 Q4	$754	Sell	5 -2	-29%	-$311	﹤0.01%	919
2024 Q3	$1.09K	Buy	7 +2	+40%	+$299	﹤0.01%	883
2024 Q2	$684	Buy	+5	New	+$685	﹤0.01%	887
2024 Q1	–	Sell	-1	Closed	-$138	–	1013
2023 Q4	$138	Sell	1 -33	-97%	-$4.34K	﹤0.01%	1066
2023 Q3	$4.16K	Sell	34 -2	-6%	-$266	﹤0.01%	712
2023 Q2	$5.01K	Sell	36 -157	-81%	-$21.6K	﹤0.01%	643
2023 Q1	$27.3K	Buy	193 +37	+24%	+$5.29K	0.01%	321
2022 Q4	$24.4K	Buy	156 +113	+263%	+$16.2K	0.01%	295
2022 Q3	$5K	Buy	+43	New	+$5.66K	﹤0.01%	477

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Raleigh Capital Management's DGX Position: Q2 2026 in Review

Raleigh Capital Management reduced its Quest Diagnostics (DGX) stake by 68% in Q2 2026, selling an estimated $3.34K and leaving 8 shares worth $1.7K. The position accounts for ﹤0.01% of the portfolio, ranked #443.

Raleigh Capital Management first reported a position in DGX in Q3 2022 and has held it in 11 quarters since. The position peaked at $27.3K in Q1 2023. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Raleigh Capital Management held 8 shares of Quest Diagnostics worth $1.7K as of Q2 2026.
Raleigh Capital Management sold 17 Quest Diagnostics shares in Q2 2026, an estimated $3.34K.
Quest Diagnostics made up ﹤0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #443 holding.
Raleigh Capital Management first reported a position in Quest Diagnostics in Q3 2022 and has held it in 11 quarters since.
Raleigh Capital Management's Quest Diagnostics position peaked at $27.3K in Q1 2023.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.